Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke

Annals of Neurology

Volumn 58, Issue 3, 2005, Pages 351-361

  Meschia, James F ^a   Brott, Thomas G ^a   Brown Jr , Robert D ^b   Crook, Richard ^a   Worrall, Bradford B ^c   Kissela, Brett ^d   Brown, W Mark ^e   Rich, Stephen S ^e   Case, L Douglas ^e   Evans, E Whitney ^f   Hague, Stephen ^f   Singleton, Andrew ^f   Hardy, John ^f  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV D; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FEMALE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; HAPLOTYPE; HEREDITY; HUMAN; ICELAND; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PRIORITY JOURNAL; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHROMOSOME MAPPING; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SIBLINGS;

EID: 24644505715     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20585     Document Type: Article

References (29)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-1276.
2. Rothwell PM, Coull AJ, Giles MF, et al, for the Oxford Vascular Study. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363:1925-1933.
3. Brown RD, Whisnant JP, Sicks JD, et al. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-380.
4. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004;35:212-227.
5. Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH, et al. Localization of a susceptibility gene for common forms of stroke to 5q12. Am J Hum Genet 2002;70:593-603.
6. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 2003;35:131-138.
7. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233-239.
8. Helgadottir A, Gretarsdottir S, St Clair D, et al. Association between the gene encoding 5-lipoxygenase activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005;76:505-509.
9. Meschia JF, Brott TG, Brown RD Jr, et al. The Ischemic Stroke Genetics Study (ISGS) protocol. BMC Neurol 2003;3:4.
10. Meschia JF, Brown RD Jr, Brott TG, et al. The Siblings With Ischemic Stroke Study (SWISS) protocol. BMC Med Genet 2002;3:1.
11. WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol 1988;41:105-114.
12. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
13. O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 1998;63:259-266.
14. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 1996;58:1347-1363.
15. Kong A, Cox NJ. Allele-sharing models: LOD scores and accurate linkage tests. Am J Hum Genet 1997;61:1179-1188.
16. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
17. Green LE, Lange EM, Langefeld CD. Power comparison of phase-known versus phase-unknown haplotype analyses for case-control designs. Am J Hum Genet 2001(suppl);69:1948 (Abstract).
18. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995;11:241-247.
19. Lõhmussaar E, Gschwendtner A, Mueller JC, et al. ALOX5AP gene and the PDE4D gene in a Central European population of stroke patients. Stroke 2005;36:731-736.
20. Ariga M, Neitzert B, Nakae S, et al. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 2004;173:7531-7538.
21. Kohyama T, Liu X, Wen F-Q, et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 2002;26:694-701.
22. Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 2004;25:430-436.
23. Kondo K, Umemura K, Miyaji M, Nakashima M. Milrinone, a phosphodiesterase inhibitor, suppresses intimal thickening after photochemically induced endothelial injury in the mouse femoral artery. Atherosclerosis 1999;142:133-138.
24. Favot L, Keravis T, Holl V, et al. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Hemost 2003;90:334-343.
25. Favot L, Keravis T, Lugnier C. Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost 2004;92:634-645.
26. Haralambieva IH, Iankov ID, Ivanova PV, et al. Chlamydophila pneumoniae induces p44/p42 mitogen-activated protein kinase activation in human fibroblasts through Toll-like receptor 4. J Med Microbiol 2004;53:1187-1193.
27. Jacob C, Martin-Chouly C, Lagente V. Type 4 phosphodiesterase-dependent pathways: role in inflammatory processes. Therapie 2002;57:163-168.
28. Sanz MJ, Alvarez A, Piqueras L, et al. Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation. Br J Pharmacol 2002;135:1872-1881.
29. Blease K, Burke-Gaffney A, Hellewell PG. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 1998;124:229-237.